Nefroprotección clásica: inhibidores del sistema renina angiotensina aldosterona

Leon, 2019, The use of renin-angiotensin system inhibitors in patients with chronic kidney disease, Can J Cardiol., 35, 1220, 10.1016/j.cjca.2019.06.029

2013, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease, Kidney Int Suppl., 3, 1

Galve, 2008, Bloqueo combinado del SRAA en la enfermedad CV. ¿Qué sabíamos hasta ahora?, Rev Esp Cardiol Supl., 8, 39E

Braam, 1996, Renal responses to antagonism of the renin-angiotensin system, Curr Opin Nephrol Hypertens., 5, 89, 10.1097/00041552-199601000-00015

Fogo, 2000, The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis, Am J Kidney Dis., 35, 179, 10.1016/S0272-6386(00)70324-6

Kasiske, 1993, Effect of antihypertensive therapy on the kidney in persons with diabetes: A meta-regression analysis, Ann Intern Med., 118, 129, 10.7326/0003-4819-118-2-199301150-00009

Navis, 2002, High-dose ACE inhibition: Can it improve renoprotection?, Am J Kidney Dis., 40, 664, 10.1053/ajkd.2002.36005

Robles Pérez-Monteoliva, 2021, Maximum doses of renin-angiotensin axis blockers in diabetic nephropathy? [¿Dosis máximas de bloqueantes del eje renina-angiotensina en nefropatía diabética?], Med Clin., 157, 20, 10.1016/j.medcli.2021.01.007

2001, Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data, Ann Intern Med., 134, 370, 10.7326/0003-4819-134-5-200103060-00009

Hamilton, 2003, Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy: A meta-analysis, Pharmacotherapy., 23, 909, 10.1592/phco.23.7.909.32726

Strippoli, 2004, Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review, BMJ., 329, 828, 10.1136/bmj.38237.585000.7C

Makino, 2007, Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes, Diabetes Care., 30, 1577, 10.2337/dc06-1998

KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney International 2022; 102 (Suppl 5S), S1-S127. Disponible en: https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf

Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group (2021). KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney international 2021; 99(3S): S1-S87. Disponible en: https://doi.org/10.1016/j.kint.2020.11.003

1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy, Lancet., 349, 1857, 10.1016/S0140-6736(96)11445-8

Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease results from the AASK trial, JAMA., 288, 2421, 10.1001/jama.288.19.2421

Jafar, 2001, Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data, Ann Intern Med., 135, 73, 10.7326/0003-4819-135-2-200107170-00007

Sharma, 2011, Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease, Cochrane Database Syst Rev., 10.1002/14651858.CD007751.pub2

Overlack, 1996, ACE inhibitor-induced cough and bronchospasm. Incidence, mechanisms and management, Drug Saf., 15, 72, 10.2165/00002018-199615010-00006

Phillips, 2007, Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: A quantitative review of data from randomized clinical trials, Arch Intern Med., 167, 1930, 10.1001/archinte.167.18.1930

Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial, Lancet., 372, 547, 10.1016/S0140-6736(08)61236-2

Garcia Sanchez, 2022, Treatments for chronic kidney disease: A systematic literature review of randomized controlled trials, Adv Ther., 39, 193, 10.1007/s12325-021-02006-z

Shabaka, 2021, Therapeutic insights in chronic kidney disease progression, Front Med (Lausanne)., 8, 645187, 10.3389/fmed.2021.645187

Bakris, 2000, Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?, Arch Intern Med., 160, 685, 10.1001/archinte.160.5.685

Clase, 2020, Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference, Kidney Int., 97, 42, 10.1016/j.kint.2019.09.018